Public information according to the provisions of Directive 2001/18/EC
File:
Trial reference:
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B
Doc type: